Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bart Spiessens

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2019
A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung CancerBenjamin Dizier, Andrea Callegaro, Muriel Debois, et al.
Lancet (London, England)|October 19, 2004
Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trialPedro L Alonso, Jahit Sacarlal, John J Aponte, et al.
Lancet (London, England)|July 3, 2007
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trialJorma Paavonen, David Jenkins, F Xavier Bosch, et al.
NPJ Vaccines|December 18, 2020
Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidateRamon Roozendaal, Jenny Hendriks, Thierry van Effelterre, et al.
The New England Journal of Medicine|April 21, 2021
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19Jerald Sadoff, Glenda Gray, An Vandebosch, et al.
The New England Journal of Medicine|February 9, 2022
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.SJerald Sadoff, Glenda Gray, An Vandebosch, et al.
The Lancet. Oncology|June 18, 2018
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trialBrigitte Dreno, John F Thompson, Bernard Mark Smithers, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2019
A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung CancerBenjamin Dizier, Andrea Callegaro, Muriel Debois, et al.
Lancet (London, England)|October 19, 2004
Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trialPedro L Alonso, Jahit Sacarlal, John J Aponte, et al.
Lancet (London, England)|July 3, 2007
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trialJorma Paavonen, David Jenkins, F Xavier Bosch, et al.
NPJ Vaccines|December 18, 2020
Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidateRamon Roozendaal, Jenny Hendriks, Thierry van Effelterre, et al.
The New England Journal of Medicine|April 21, 2021
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19Jerald Sadoff, Glenda Gray, An Vandebosch, et al.
The New England Journal of Medicine|February 9, 2022
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.SJerald Sadoff, Glenda Gray, An Vandebosch, et al.
The Lancet. Oncology|June 18, 2018
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trialBrigitte Dreno, John F Thompson, Bernard Mark Smithers, et al.
Pageof 4